Studies of minimal residual disease in acute lymphocytic leukemia

Hematology/Oncology Clinics of North America

Volumn 14, Issue 6, 2000, Pages 1289-1305

  Stock, Wendy ^a   Estrov, Zeev ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; T LYMPHOCYTE RECEPTOR;

ACUTE LYMPHOCYTIC LEUKEMIA; CANCER REGRESSION; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE REARRANGEMENT; HUMAN; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; NUCLEOTIDE SEQUENCE; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SOUTHERN BLOTTING; STEM CELL TRANSPLANTATION;

EID: 0033637410     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70187-8     Document Type: Article

References (80)

1. Multiple rearranged immunoglobulin genes in childhood acute lymphoblastic leukemia of precursor B-cell origin
2. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals
3. Detection of ALL1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t(4;11) translocation
4. Minimal residual disease in childhood acute lymphoblastic leukemia: Analysis of patients in continuous complete remission or with consecutive relapse
5. Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction
6. The use of flow cytometry to detect minimal residual disease in acute leukemia
7. The immunological detection of minimal residual disease in acute leukemia
8. Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance
9. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia
10. Expression of AML1-ETO fusion transcripts and detection of minimal resiudal disease in t(8;21)-positive acute myeloid leukemia
11. A prospective study of ing of the ALL1/AF4 transcript m patients with t(4;11) acute lymphoblastic leukemia
12. Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL-1/AF- 4 positive acute lymphoblastic leukemia
13. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia
14. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia
15. Qunatitative PCR techniques and applications
16. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia
17. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia
18. BCL-2/J(H) rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases
19. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphobiastic leukemia
20. Flow cytometric deterination of atypical antigen expression in acute leukemia for the study of minimal residual disease
21. Monitoring of BCR-ABL expression using 'real-time' RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation
22. Quantitation of minimal residual disease in acute leukemia and myelodysplastic syndromes in complete remission by myelogenous molecular cytogenetics of progenitor cells
23. Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission
24. Detection of residual disease in acute lymphoblastic leukemia of childhood
25. The clinical significance of detection of residual disease in childhood ALL
26. Dose-intensive therapy for adult acute lymphoblastic leukemia
27. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia
28. Bone marrow transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
29. Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response
30. Backtracking leukemia to birth: Identification of clonotypic gene fusion sequences in neonatal blood spots
31. Chimeric BCR-ABL messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive acute lymphoblastic leukemia
32. Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia
33. Silence of the leukemic clone
34. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome
35. Real time quantitative PCR
36. Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4;11)(q21;q23)
37. E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13)
38. Flow cytometric detection of rare normal human marrow cells with immunophenotypes characteristic of acute lymphoblastic leukemia cells
39. Detection and clinical relevance of genetic abnormalities in pediatric acute lymphoblastic leukemia: A comparison between cytogenetic and polymerase chain reaction analysis
40. Cellular phenotypes of normal and leukemic hemopoietic cells determined by analysis with selected antiblody combinations
41. Pre-pre-B acute lymphoblastic leukemia: High frequency of alternatively spliced ALL1-AF 4 transcripts and absence of minimal residual disease during complete remission
42. Persistence of the AML1/ETO fusion transcript in patients treatmed with allgeneic bone marrow transplantation for t(8;21) leukemia
43. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia
44. Minimal residual disease status as a predictor of relaspe after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia
45. Long-term follow-up of minimal residual disease in childhood acute lymphoblastic leukemia patients by polymerase chain reaction analysis of multiple clone-specific or malignancy-specific gene markers
46. Immunophenotype and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: Results of the German multicenter trials GMALL 03/87 and 04/89
47. Combined cytogenetic FISH and molecular analysis in acute promyelocytic leukaemia at diagnosis and in complete remission
48. Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: Possible eradication of minimal residual disease by marrow transplantation
49. Modern molecular diagnostics and the management of hematological malignancies
50. Real time quantitative PCR
51. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogenic IgH probes and the polymerase chain reaction
52. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission
53. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes
54. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TALl deletions as PCR targets
55. The significance of detection of minimal residual disease in childhood acute lymphoblastic leukemia
56. Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL)
57. Reverse transcriptase/polymerase chain reaction follow-up and minimal residual disease detection in t(1;19)-positive acute lymphoblastic leukemia
58. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation
59. Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction
60. PCR-based detection of unique immunoglobulin V-D-J gene rearrangements in acute lymphoblastic leukemia predicts relapse after allogeneic bone marrow transplantation
61. Polymerase chain reaction detection of BCR-ABL fusion transcript after allogeneic marrow transplantation for CML: Results and implications in 346 patients
62. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia
63. Partial tandem duplications of the MLL gene are detectable in peripheral blood and bone marrow of nearly all healthy donors
64. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA
65. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia
66. Usefulness of detection of minimal residual disease by 'hypermetaphase' fluorescent in situ hybridization after allogeneic BMT for chronic myelogenous leukemia
67. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia
68. Rearrangement status of the malignant cell determines type of secondary IgH rearrangement (V-replacement or V to DJ joining) in childhood B precursor acute lymphoblastic leukemia
69. Quantitative molecular monitoring of BCR/ABL transcripts in adult acute lymphoblastic leukemia (ALL) using a real-time PCR assay: Pilot study from the Cancer and Leukemia Group B (CALGB 8762)
70. Five-dimensional flow cytometry as a new approach for blood and bone marrow differentials
71. Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation
72. Reflection on the detection and treatment of leukemia
73. Detection of minimal residual disease in acute leukemia patients
74. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction
75. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood
76. Late relapsing childhood lymphoblastic leukemia
77. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia
78. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: Implications for residual disease detection
79. Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation
80. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: A Cancer and Leukemia Group B Study (8762)